CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Efavirenz, emtricitabine, tenofovir disoproxil fumarate

Last Updated: October 30, 2007
Result type: Reports
Project Number: SR0111-000
Product Line: Reimbursement Review

Generic Name: Efavirenz, emtricitabine, tenofovir disoproxil fumarate

Brand Name: Atripla

Manufacturer: Bristol-Myers Squibb and Gilead Sciences

Therapeutic Area: HIV

Indications: HIV

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 17, 2008

Recommendation Type: List with clinical criteria and/or conditions